Chickenpox Vaccine Global Market Report 2024

Chickenpox vaccines stimulate the immune response, triggering antibody production against varicella-zoster viruses, preventing future infections. The virus causes highly contagious chickenpox (VZV).

The primary types of chickenpox vaccines are the monovalent varicella vaccine and the combination varicella vaccine. The monovalent varicella vaccine contains a live, weakened virus highly effective in generating antibodies, with a single dose inducing antibody formation in about 97% of school-aged recipients. These vaccines have diverse applications, including immunization against mumps, measles, rubella, varicella, herpes zoster, and chickenpox. They are utilized across various end-users such as hospitals, clinics, and other medical settings.

The chickenpox vaccine market research report is one of a series of new reports from The Business Research Company that provides chickenpox vaccine optical components market statistics, including chickenpox vaccine optical components industry global market size, regional shares, competitors with a chickenpox vaccine optical components market share, detailed chickenpox vaccine optical components market segments, market trends and opportunities, and any further data you may need to thrive in the chickenpox vaccine optical components industry. This chickenpox vaccine optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chickenpox vaccine market size has grown strongly in recent years. It will grow from $3.38 billion in 2023 to $3.61 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. Historical growth can be attributed to various factors including the development of vaccines, regulatory approvals for their usage, disease incidence rates, vaccination policies, and public health initiatives aimed at promoting immunization.

The chickenpox vaccine market size is expected to see strong growth in the next few years. It will grow to $4.64 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. Anticipated growth in the upcoming period is tied to factors such as public perception and trust, preparedness for pandemics, continued research and development efforts, growing demand in emerging markets, and ongoing development of healthcare infrastructure. Major trends expected in this forecast period encompass initiatives focused on vaccine education campaigns, the implementation of adverse event monitoring systems, strategies for vaccine pricing, advancements in innovation, and the utilization of AI in vaccine development and distribution.

The anticipated rise in the prevalence of chickenpox disease is set to significantly propel the expansion of the chickenpox vaccine market. Chickenpox, caused by the varicella-zoster virus (VZV), manifests as a highly contagious infection characterized by a blister-such as rash accompanied by itching. The surge in reported cases of chickenpox underscores the heightened necessity for varicella vaccine immunization, consequently driving up the demand for chickenpox vaccines. As an illustration, a report released by the Centers for Disease Control and Prevention (CDC) in April 2021 highlighted that in the USA alone, approximately 4 million individuals contract chickenpox annually, leading to over 10,500 hospitalizations and tragically resulting in between 100 and 150 fatalities. This escalating prevalence of chickenpox disease stands as a primary catalyst propelling the growth trajectory of the chickenpox vaccine market.

The projected upsurge in the chickenpox vaccine market is expected to be fueled by a growing recognition of the advantages associated with vaccination. Vaccination, a medical procedure involving the introduction of weakened or inactive forms of viruses or bacteria into the body, has gained increased attention due to its role in mitigating diseases. Elevated awareness regarding the benefits of the chickenpox vaccine is instrumental in promoting higher vaccination rates, consequently leading to a decline in the overall incidence of the disease. Notably, the World Health Organization (WHO) released its Global Vaccine Market Report 2022 in November 2022, highlighting significant disparities driven by limited vaccine supply and unequal distribution globally. The report indicated a substantial increase in the vaccine supply, with approximately 16 billion doses, valued at $141 billion, supplied in 2021-nearly three times the market volume observed in 2019, predominantly attributed to the production of COVID-19 vaccines. This heightened awareness regarding the advantages of vaccination stands as a key driver propelling the growth of the chickenpox vaccine market.

The prevailing trend in the chickenpox vaccine market revolves around novel drug developments aimed at enhancing efficacy and introducing innovative derivatives. Leading companies within the market are focused on advancing new drugs to reinforce their position. Notably, in November 2022, Sinovac Biotech Ltd., a China-based company specializing in vaccine research, development, and manufacturing, announced a significant milestone: the World Health Organization (WHO) granted prequalification status to its live attenuated chickenpox (varicella) vaccine. This vaccine stands as the world's first varicella vaccine to receive such prequalification. The vaccine draws from the Oka strain and is cultivated in the exclusive Human Diploid Cell (SV-1 strain) developed by SINOVAC. The production process involves cultivating and harvesting the virus, incorporating stabilizers, and freeze-drying it. During a phase III efficacy trial among children aged 1 to 12 years, the vaccine demonstrated a remarkable 97.1% seroconversion rate in the vaccinated group. Moreover, its efficacy against varicella and breakthrough varicella stood at 87.1% and 89.2%, respectively. Notably, the vaccine showcased 100% efficacy in preventing both mild and severe conditions associated with chickenpox. This innovative vaccine represents a significant advancement in bolstering the arsenal against varicella infection within the market.

Major players in the chickenpox vaccine market are heavily focusing on research and development investments to introduce innovative vaccine formulations. Research and development (R&D) investments entail the allocation of funds by various entities, including companies, governments, or research institutions, toward activities aimed at fostering innovation and progress in their respective fields. For example, in February 2022, as reported by GOV.UK, the UK government earmarked £10 million specifically for vaccine research directed at combating potential epidemics in developing nations. This substantial investment forms part of a larger commitment wherein £134 million of Official Development Assistance (ODA) was pledged between 2016 and 2021 for vaccine development targeting epidemic diseases. The government's UK Vaccine Network has selected 22 research projects that aim to tackle viruses such as Ebola, Lassa fever, and Zika. These investments underscore a significant commitment to advancing vaccine research to address critical health challenges and enhance global public health efforts.

In July 2022, GC LabCell, a prominent biotechnology company based in South Korea, finalized a definitive merger agreement with GC Cell Corporation, also based in South Korea, which specializes in the production of chickenpox vaccine. This strategic merger unites two distinguished biopharmaceutical entities from South Korea, each with its unique strengths and portfolios. The combined entity benefits from highly complementary portfolios, bolstered by an extensive cell therapy research and development pipeline. Additionally, the merger leverages cutting-edge manufacturing capabilities, positioning the consolidated company to expedite its growth trajectory significantly. This strategic move is expected to foster accelerated growth and enhance value creation within the biopharmaceutical landscape.

Major companies operating in the chickenpox vaccine market report are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi Pasteur, AstraZeneca plc., GlaxoSmithKline plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Zydus Lifesciences Limited, Green Cross Corporation, Sinovac Biotech Ltd., GC Biopharma Corp., Emergent BioSolutions Inc., Bharat Biotech, Novo Medi Sciences Pvt. Ltd., Hualan Biological Engineering Inc., Chongqing Zhifei Biological Products Co. Ltd., Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Valneva SE, Serum Institute of India, Shenzhen Kangtai Biological Products Co. Ltd., SK Bioscience Co.Ltd., Biological E. Limited, PanGen Biotech Inc., Bio-Med, Parc-vaccinogene en Instituut Pasteur, Lucky Chemical Industrial Corporation, Biocad India Private Limited, Virchow Biotech Pvt. Ltd.

North America was the largest region in the chickenpox vaccine market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chickenpox vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chickenpox vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chickenpox vaccines market consists of sales of single-antigen varicella vaccines and mixed-antigen varicella vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chickenpox Vaccine Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chickenpox vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chickenpox vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chickenpox vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Vaccine: Monovalent varicella vaccine; Combination varicella vaccine
• 2) By Application: Mumps, Measles, Rubella, And Varicella Immunization; Herpes Zoster Immunization; Chickenpox Vaccination
• 3) By End-Users: Hospitals; Clinics; Other End-Users
• Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Novartis AG; Sanofi Pasteur; AstraZeneca plc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.